Tumori最新文献

{"title":"Outcomes in patients with <i>BRAF</i>^V600-mutated melanoma and brain metastases at baseline treated with dabrafenib plus trametinib.","authors":"Massimo Aglietta, Vanna Chiarion-Sileni, Paolo Fava, Massimo Guidoboni, Roberta Depenni, Alessandro Minisini, Francesca Consoli, Paolo Antonio Ascierto, Gaetana Rinaldi, Maria Banzi, Riccardo Marconcini, Rossana Gueli, Virginia Ferraresi, Marco Tucci, Giuseppe Tonini, Giovanni Lo Re, Michele Guida, Michele Del Vecchio, Ilaria Gioia Marcon, Paola Queirolo","doi":"10.1177/03008916231179251","DOIUrl":"10.1177/03008916231179251","url":null,"abstract":"<p><strong>Background: </strong>Brain metastases (BM) and lactate dehydrogenase (LDH) levels above the upper limit of normal (ULN) are associated with poor prognosis in patients with melanoma. Although treatment with the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib have demonstrated long-term clinical benefit in patients with melanoma, data on their efficacy in patients with BM are limited.</p><p><strong>Methods: </strong>DESCRIBE Italy is an observational, retrospective, real-world study evaluating dabrafenib plus trametinib in 499 patients with <i>BRAF</i>^V600-mutant stage III unresectable or stage IV melanoma from various sites across Italy. Here, we analyzed the clinical outcomes for the subgroup of patients receiving first-line treatment and presenting with BM at diagnosis and assessed the impact of predictive factors such as LDH levels and the presence of other metastases on median progression-free survival (mPFS).</p><p><strong>Results: </strong>Overall, 325 evaluable patients were on first-line therapy and are the focus of this analysis; of these, 76 patients (23.4%) had BM at baseline. mPFS was lower for patients with BM at baseline compared with overall patients (8.7 months vs 9.3 months, respectively). Patients with BM at diagnosis and LDH >ULN had a considerably shorter mPFS compared with patients with LDH ⩽ULN (5.3 months vs 9.9 months, respectively). mPFS was noticeably longer for patients with cerebral metastases only compared with patients with cerebral and other metastases (15.0 months vs 8.7 months, respectively).</p><p><strong>Conclusions: </strong>Dabrafenib plus trametinib showed effectiveness in a real-world population of patients with advanced <i>BRAF</i>^V600-mutated melanoma and BM at baseline, supporting its use in this population with poor outcomes.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"537-545"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10702308/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9815334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of inter-observer variability on first axillary level dosimetry in breast cancer radiotherapy: An AIRO multi-institutional study.","authors":"Maria Cristina Leonardi, Matteo Pepa, Mattia Zaffaroni, Maria Giulia Vincini, Rosa Luraschi, Sabrina Vigorito, Anna Morra, Samantha Dicuonzo, Giovanni Carlo Mazzola, Marianna Alessandra Gerardi, Maria Alessia Zerella, Domenico Cante, Edoardo Petrucci, Giuseppina Borzì, Maristella Marrocco, Matteo Chieregato, Luciano Iadanza, Francesca Lobefalo, Marco Valenti, Anna Cavallo, Serenella Russo, Marika Guernieri, Tiziana Malatesta, Ilaria Meaglia, Marco Liotta, Isabella Palumbo, Marta Marcantonini, Emilio Mezzenga, Sara Falivene, Cecilia Arrichiello, Maria Paola Barbero, Giovanni Battista Ivaldi, Gianpiero Catalano, Cristiana Vidali, Caterina Giannitto, Antonella Ciabattoni, Icro Meattini, Cynthia Aristei, Roberto Orecchia, Federica Cattani, Barbara Alicja Jereczek-Fossa","doi":"10.1177/03008916231196801","DOIUrl":"10.1177/03008916231196801","url":null,"abstract":"<p><p>This study quantified the incidental dose to the first axillary level (L1) in locoregional treatment plan for breast cancer. Eighteen radiotherapy centres contoured L1-L4 on three different patients (P1,2,3), created the L2-L4 planning target volume (single centre planning target volume, SC-PTV) and elaborated a locoregional treatment plan. The L2-L4 gold standard clinical target volume (CTV) along with the gold standard L1 contour (GS-L1) were created by an expert consensus. The SC-PTV was then replaced by the GS-PTV and the incidental dose to GS-L1 was measured. Dosimetric data were analysed with Kruskal-Wallis test. Plans were intensity modulated radiotherapy (IMRT)-based. P3 with 90° arm setup had statistically significant higher L1 dose across the board than P1 and P2, with the mean dose (Dmean) reaching clinical significance. Dmean of P1 and P2 was consistent with the literature (77.4% and 74.7%, respectively). The incidental dose depended mostly on L1 proportion included in the breast fields, underlining the importance of the setup, even in case of IMRT.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"570-575"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10702305/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10186122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complete pathological response of hormone receptor positive invasive breast cancer in a patient with multiple myeloma treated with ixazomib.","authors":"Martina Dameri, Alessandro Garlaschi, Paola Cuccarolo, Andrea Ceccardi, Mario Stabile, Irene Valente, Licia Gristina, Massimo Calabrese, Alberto Ballestrero, Alberto Tagliafico, Gabriele Zoppoli","doi":"10.1177/03008916231176586","DOIUrl":"10.1177/03008916231176586","url":null,"abstract":"<p><p>Multiple myeloma is a hematological cancer characterized by relapse after treatment and poor prognosis. Ixazomib, a second-generation protease inhibitor, is one of the most recently available treatments for relapsed or refractory multiple myeloma, while it has also shown good potential as antitumoral agent in preclinical solid tumor models such as breast cancer cell lines. Here we report the case of a 68-year-old female with multiple myeloma and an incidental cT1b (9 mm) hormone receptor positive breast cancer lesion that showed a complete pathological response to a three-month combination therapy with Ixazomib, bendamustine and dexamethasone and no signs of disease relapse during the later follow-up. This is the first case report describing such clinical outcome in breast cancer following Ixazomib, bendamustine and dexamethasone combination therapy. To investigate the potential antitumoral activity of Ixazomib in breast cancer, we performed <i>in vitro</i> experiments using two hormone receptor positive breast cancer cell lines. We assessed the synergism between Ixazomib and bendamustine and the antiproliferative effect of Ixazomib. We found no synergistic interaction between the two drugs, while Ixazomib alone showed an antiproliferative effect against tumoral cells, suggesting that this drug has been responsible for tumor regression in our case.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"NP14-NP20"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10702304/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9615721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"End-of-Life transfusion support at hospice and pediatric oncology unit: Bridging the gap between benefits and therapeutic alliance.","authors":"Olga Nigro, Marta G Podda, Federico Pellegatta, Elisabetta Schiavello, Carlo A Clerici, Igor Catalano, Giovanna Visconti, Marco Albarini, Roberto Luksch, Monica Terenziani, Andrea Ferrari, Michela Casanova, Veronica Biassoni, Cristina Meazza, Filippo Spreafico, Giovanna Gattuso, Giovanna Sironi, Nadia Puma, Luca Bergamaschi, Stefano Chiaravalli, Maura Massimino","doi":"10.1177/03008916231168670","DOIUrl":"10.1177/03008916231168670","url":null,"abstract":"<p><strong>Objectives: </strong>Although transfusion support is commonly used in oncological palliative care, there is still a paucity of literature. We examined the transfusion support provided in the terminal stage of the disease and compared the approach at a pediatric oncology unit and a pediatric hospice.</p><p><strong>Case description: </strong>This case series analyzed patients treated at the Fondazione IRCCS Istituto Nazionale dei Tumori di Milano (INT)'s pediatric oncology unit who died between January 2018 and April 2022. We compared these with those who died at the VIDAS hospice and analyzed the number of complete blood counts taken in a patient's last 14 days of life, and the number of transfusions performed in the same period.We analyzed 44 patients (22 in pediatric oncology unit; 22 in hospice) in total. Twenty-eight complete blood counts were performed (7/22 patients at the hospice; 21/22 patients at the pediatric oncology unit). Nine patients were given transfusions, three at the hospice, six at our pediatric oncology unit (24 transfusions in total): 20 transfusions at the pediatric oncology unit, four at the hospice. In total 17/44 patients were given active therapies in the last 14 days of life: 13 at the pediatric oncology unit, four at the pediatric hospice. Ongoing cancer treatments did not correlate with a greater likelihood of receiving a transfusion (p=0.91).</p><p><strong>Conclusions: </strong>The hospice's approach was more conservative than the pediatric oncology one. In the in-hospital setting, the need for a transfusion cannot always be decided on by a combination of numerical values and parameters alone. The family's emotional-relational response must be considered too.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"NP6-NP10"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9431867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current practices of follow-up programs for childhood cancer survivors in Italy.","authors":"Monica Terenziani, Alberto Eugenio Tozzi, Laura Diaco, Eleonora Biasin, Alessandro Cattoni, Ileana Croci, Donatella Fraschini, Giovanna Giorgiani, Riccardo Haupt, Monica Muraca, Marta Pillon, Giovanna Sironi, Maria Grazia Valsecchi, Angela Mastronuzzi","doi":"10.1177/03008916231185981","DOIUrl":"10.1177/03008916231185981","url":null,"abstract":"<p><strong>Introduction: </strong>Quality of life in childhood cancer survivors is largely affected by survivorship care and transition from treatment to long-term follow-up (LTFU). Referring to evidence-based recommendations, we wanted to evaluate LTFU care for survivors through a survey among the Italian Association for Pediatric Hematology-Oncology (AIEOP) centers. The project aimed to evaluate the availability of services in Italy, investigate strengths and weaknesses, analyze improvements of awareness in the field, and identify the gaps that need to be addressed by different centers.</p><p><strong>Methods: </strong>Together with the family representatives, on behalf of AIEOP's Late Effects Working Group, we developed a questionnaire on assisting childhood cancer survivors. All AIEOP centers received one questionnaire including information on local health system organizations; LTFU for childhood cancer survivors; services for adult survivors of childhood cancer; information provided to survivors/caregivers and care plan delivery.</p><p><strong>Results: </strong>Forty-eight AIEOP centers were contacted and 42 replied, with a response rate of 87.5%. The majority of respondents confirmed their interest in assisting patients with a survivorship care plan (95.2%), regardless of a clinic or dedicated staff.</p><p><strong>Discussion: </strong>This is the first overview of LTFU in Italy, which provides detailed results at national levels, prompting consideration of improvements in the last decade. Although there is a high level of interest in survivorship care, many centers lack resources to implement such programs. The identification of these challenges is useful for planning future strategies.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"555-561"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10702306/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9770128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Demyelinating polyradiculoneuropathy during dabrafenib and trametinib treatment for metastatic melanoma: A case report.","authors":"Marta Venturelli, Stefano Greco, Cinzia Baldessari, Giuseppe Pugliese, Roberta Depenni, Massimo Dominici","doi":"10.1177/03008916231202102","DOIUrl":"10.1177/03008916231202102","url":null,"abstract":"<p><strong>Background: </strong>Melanoma is an aggressive malignancy, historically characterized with a poor prognosis and few treatment options. The advent of target therapy with BRAF and MEK inhibitors, as well as immunotherapy, changed this scenario and improved the prognosis of patients with BRAF V600E mutation. These therapies are generally well tolerated. Neurological toxicities, especially polyradiculopathy, are very rare with BRAF inhibitors and MEK inhibitors although some cases have been described in recent years, regardless of the type of target therapies combination used.</p><p><strong>Case report: </strong>We report the case of a patient with BRAF V600E-mutated metastatic melanoma treated with dabrafenib and trametinib who has developed a demyelinating polyradiculoneuropathy.</p><p><strong>Conclusion: </strong>This case, once more, should draw our attention to the possibility of rare, but potentially serious side effects, even in the case of generally well-tolerated treatments. Especially in the presence of side effects, it is important a close relationship between clinicians and patients for the management of adverse events and the choice of the best treatment strategy.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":"109 6","pages":"NP21-NP26"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138483105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Have we made progress in taking care of adolescents and young adults with cancer? Results of a European multi-professional survey.","authors":"Ivana Bozovic Spasojevic, Andrea Ferrari, Johan De Munter, Ashley Gamble, Assia Konsoulova-Kirova, Katie Rizvi, Carina Schneider, Marie Balsat, Anna Castleton, Leila Gofti-Laroche, Anita Kienesberger, Beate Timmermann, Josef Vormoor, Emmanouil Saloustros, Daniel P Stark","doi":"10.1177/03008916231183477","DOIUrl":"10.1177/03008916231183477","url":null,"abstract":"<p><strong>Background: </strong>It is well documented that traditional health care models do not meet the specific needs of Adolescents and Young Adults (AYA) cancer patients.</p><p><strong>Methods: </strong>We explore a map of the development of age-specific AYA cancer care across Europe, from the perspective of healthcare professionals with an interest in AYA care, in order to understand the specific challenges and map progress over time. An on-line survey was developed by international professional cancer organisations.</p><p><strong>Results: </strong>We had 377 respondents from 60 countries. The majority of respondents were physicians 298 (79%), a minority of survey respondents (39, 10.4%) work exclusively with AYA patients, most respondents declared substantial and routine clinical service collaborations to provide care and treatment to AYA with cancer. Policy for the multidisciplinary management of AYA cancer patients commonly appears in Europe now, and was reported by 234 (78.52%) respondents. Specific professional training for AYA cancer care is not uniformly available.</p><p><strong>Conclusion: </strong>There is considerable opportunity for many organisations to work together in raising the profile of AYA cancer related issues, in providing education and in encouraging research and collaboration.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"546-554"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10216787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Upper-neck irradiation versus standard whole-neck irradiation in nasopharyngeal carcinoma: A systematic review and meta-analysis.","authors":"Francesca De Felice, Claudia Marchetti, Maria Serpone, AnnaMaria Camarda, Barbara Vischioni, Rossana Ingargiola, Daniela Musio, Ester Orlandi","doi":"10.1177/03008916231154765","DOIUrl":"10.1177/03008916231154765","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the role of upper-neck irradiation versus standard whole-neck irradiation in patients with N0-1 nasopharyngeal carcinoma.</p><p><strong>Methods: </strong>We conducted a PRISMA guideline based systematic review and meta-analysis. Randomized clinical trials assessing upper-neck irradiation versus whole-neck irradiation with or without chemotherapy in non-metastatic N0-1 nasopharyngeal carcinoma patients were identified. The studies were searched on the PubMed, Embase and Cochrane library up to March 2022. Survival outcomes, including overall survival, distant metastasis-free survival and relapse-free survival, and toxicities rate were evaluated.</p><p><strong>Results: </strong>There were two randomized clinical trials with 747 samples finally included. Upper-neck irradiation had similar overall survival (hazard ratio = 0.69, 95% confidence interval = 0.37-1.30), distant metastasis-free survival (hazard ratio = 0.92, 95% confidence interval = 0.53-1.60) and relapse-free survival (risk ratio = 1.03, 95% confidence interval = 0.69-1.55) compared to whole-neck irradiation. No differences in both acute and late toxicities were recorded between upper-neck irradiation and whole-neck irradiation.</p><p><strong>Conclusion: </strong>This meta-analysis supports the potential role of upper-neck irradiation in this population of patients. Further research is needed to confirm results.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"529-536"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9282186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Observational studies - The Cinderella of the Italian research system.","authors":"Celeste Cagnazzo, Marco Basiricò, Federica Palermo, Franca Fagioli","doi":"10.1177/03008916231166469","DOIUrl":"10.1177/03008916231166469","url":null,"abstract":"<p><p>Observational trials are crucial to assess the generalizability in the real world of evidence deriving from registration studies. Despite the unquestionable importance of this type of studies, Italian researchers have had to face many obstacles over the years, mainly due to ambiguous definitions and to a complex but at the same time incomplete legislation. The regulatory adjustments to the European Regulation 536/2014 have further complicated the operating and operational framework, making observational research a real \"Cinderella\" of the Italian system.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"524-528"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9314390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of enhancement modifications in evaluating tumor response to immunotherapy in metastatic renal cell carcinoma.","authors":"Michele Dionese, Francesco Pierantoni, Elisabetta Bezzon, Enrico Cumerlato, Davide Bimbatti, Umberto Basso, Marco Maruzzo, Vittorina Zagonel","doi":"10.1177/03008916231188157","DOIUrl":"10.1177/03008916231188157","url":null,"abstract":"<p><strong>Introduction: </strong>Evaluation of tumor response according only to dimensional criteria may underestimate treatment benefit in patients treated for metastatic renal cell carcinoma (RCC). In this study we evaluated the role of lesion enhancement modifications and Choi criteria in patients affected by renal cell carcinoma treated with immunotherapy.</p><p><strong>Methods: </strong>We collected data of 60 consecutive patients (with a total of 154 measurable lesions) treated with immunotherapy (nivolumab or ipilimumab plus nivolumab) at a single Institution. We evaluated tumour response using both RECIST1.1 criteria and Choi criteria at the first radiological assessment; we subsequently associated response with progression free survival and overall survival.</p><p><strong>Results: </strong>Choi criteria found a higher rate of objective response compared to RECIST criteria (38.3% vs 18.3%). An objective response according to both criteria was associated with longer progression free survival and overall survival. Response rate for Choi did not vary according to lesion site.</p><p><strong>Conclusion: </strong>Choi criteria seemed to be able to predict clinical benefit in a higher proportion of patients with renal cell carcinoma treated with immunotherapy than RECIST criteria. Partial response according to RECIST was confirmed as a predictor of longer progression-free survival and overall survival.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"562-569"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10702307/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9886146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}